- Login
- Register & Subscribe
- Language: EN FR DE
Thursday 8 July 2010
The Lyon-based company, Poxel SA, has raised €16 million in a Series A round, enabling it to advance the Phase 2 programme for its lead compound against Type 2 diabetes. The round was led by Edmond de Rothschild Investment Partners.
Country: France
Thursday 8 July 2010
The Global Alliance for TB Drug Development has reached an agreement with the Geneva-based Drugs for Neglected Diseases initiative (DNDi) under which it will grant royalty-free rights to DNDi to develop drugs against neglected diseases.
Country: Switzerland
Wednesday 7 July 2010
The European Medicines Agency has issued a second warning about supply problems for the Genzyme Corp drug, Fabrazyme (agalsidase beta), for Fabry disease. It is recommending that, where possible, an alternative treatment be used.
Country: United Kingdom
Wednesday 7 July 2010
AstraZeneca Plc and the technology transfer arm of the UK Medical Research Council have reached an agreement to share their respective compound libraries in order to increase the prospect of finding new treatments for serious diseases.
Country: United Kingdom
Friday 2 July 2010
Eli Lilly announced that it has reached an agreement to acquire the privately-held US biotechnology company, Alnara Pharmaceuticals Inc which is developing protein therapeutics for metabolic diseases. Financial terms were not disclosed.
Country: United States
Thursday 1 July 2010
GlaxoSmithKline Plc and Genmab A/S have altered their co-development agreement for ofatumumab (Arzerra) with the result that GSK will develop the antibody for autoimmune indications. The companies will continue their collaboration in cancer.
Country: United Kingdom
Thursday 1 July 2010
Celgene Corp is set to expand its oncology franchise with an agreed cash and stock offer for Abraxis BioScience Inc of California which has a marketed treatment for metastatic breast cancer. The deal will establish Celgene in solid tumours.
Country: United States
Thursday 1 July 2010
The European Medicines Agency is proposing a new method for calculating the fees that it charges to industry for its services. The fee structure would be simplified, with fewer fees charged for applications for a marketing authorisation.
Country: United Kingdom
Wednesday 30 June 2010
Sanofi-Aventis SA is acquiring TargeGen Inc, a privately held US company that specialises in developing small-molecule kinase inhibitors for treatment of haematological malignancies.
Country: France
Tuesday 29 June 2010
SV Life Sciences said that it has raised more than $523 million for its fifth international life sciences fund which will focus on providing start-up, early stage and expansion capital to life science companies in the US and Europe.
Country: United States
Tuesday September 7 2010
Friday September 3 2010
Friday August 20 2010
Friday August 20 2010
Thursday August 19 2010